Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA

Executive Summary

Lilly and Boehringer Ingelheim's decision to withdraw the Yentreve application based upon FDA's expected negative review decision will give the companies additional time to develop a marketing strategy

You may also be interested in...



Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy

Problems with clinical trial design and/or execution identified pre-submission are the issues most likely to be resolved in advance of first FDA action, Booz Allen Hamilton's first-cycle review report finds

Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy

Problems with clinical trial design and/or execution identified pre-submission are the issues most likely to be resolved in advance of first FDA action, Booz Allen Hamilton's first-cycle review report finds

Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension

Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra

Related Content

Topics

UsernamePublicRestriction

Register

PS045355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel